<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527265</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-155 Part 1</org_study_id>
    <secondary_id>U1111-1166-5528</secondary_id>
    <nct_id>NCT02527265</nct_id>
  </id_info>
  <brief_title>Afrezza Safety and Pharmacokinetics Study in Pediatric Patients</brief_title>
  <official_title>Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza® in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      -To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1&#xD;
      diabetes mellitus (T1DM).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the ability to titrate the prandial and supplemental doses of Afrezza at each&#xD;
           meal.&#xD;
&#xD;
        -  To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4&#xD;
           to 17 years with T1DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients are expected to participate in the study for approximately 6 to 8 weeks from&#xD;
      Screening to final follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Actual">June 25, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Maximum Observed Concentration (Cmax)</measure>
    <time_frame>250 minutes post-dose</time_frame>
    <description>Insulin Cmax after a dose of Afrezza</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Time to Reach Cmax (Tmax)</measure>
    <time_frame>250 minutes post-dose</time_frame>
    <description>Insulin Tmax after a dose of Afrezza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Area Under Concentration Time Curve (AUC)</measure>
    <time_frame>250 minutes post-dose</time_frame>
    <description>Insulin AUC after a dose of Afrezza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)</measure>
    <time_frame>Using PK data collected over 250 minutes post-dose of Afrezza</time_frame>
    <description>FDKP (inert carrier excipient) calculated half life t1/2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Afrezza (Technosphere Insulin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Afrezza</intervention_name>
    <description>Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
    <arm_group_label>Afrezza (Technosphere Insulin)</arm_group_label>
    <other_name>Technosphere Insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          1. Written or oral assent from the pediatric subject and written informed consent from&#xD;
             the parent(s) or legal guardian and a witness, as required by both state and federal&#xD;
             laws and the local Institutional Review Board;&#xD;
&#xD;
          2. Children aged ≥4 and ≤17 years (enrolled sequentially into 3 age cohorts: 13 to 17, 8&#xD;
             to 12, and 4 to 7 years);&#xD;
&#xD;
          3. Clinical diagnosis of T1DM and using insulin for at least 1 year;&#xD;
&#xD;
          4. Currently receiving a regimen of basal/bolus insulin administered by MDI for at least&#xD;
             6 weeks prior to enrollment;&#xD;
&#xD;
          5. Subjects with pre-breakfast self monitored blood glucose values between 80 and 250&#xD;
             mg/dL for 5 of 7 documented daily readings obtained in the week prior to Visit 2&#xD;
             (readings to be taken using glucometer provided at Screening Visit 1) and reported via&#xD;
             the e Diary;&#xD;
&#xD;
          6. Subjects on a regimen of insulin via continuous SC insulin infusion may be enrolled if&#xD;
             they satisfy all other enrollment criteria and are willing to convert to MDI for the&#xD;
             duration of the study, beginning 6 weeks prior to enrollment. They must continue to&#xD;
             meet all enrollment criteria after converting to the MDI regimen;&#xD;
&#xD;
          7. Total daily insulin dose ≤1.5 units/kg/day with a minimum of 3 units of RAA at every&#xD;
             meal.&#xD;
&#xD;
          8. Hemoglobin A1c (HbA1c) ≥7.0% to &lt;10.0% at the time of screening;&#xD;
&#xD;
          9. Fasting serum C-peptide ≤0.3 ng/mL;&#xD;
&#xD;
         10. Forced expiratory volume in 1 second (FEV1) ≥70% of National Health and Nutrition&#xD;
             Examination Survey (NHANES) III predicted for children ≥8 years of age or Wang&#xD;
             predicted for children &lt;8 years of age;&#xD;
&#xD;
         11. Forced vital capacity ≥70% of NHANES III predicted for children ≥8 years of age or&#xD;
             Wang predicted for children &lt;8 years of age;&#xD;
&#xD;
         12. Females of childbearing potential, must use &quot;highly effective&quot; methods of&#xD;
             contraception throughout conduct of the trial&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Body mass index below 25th or above 95th percentile for age and gender according to&#xD;
             Centers for Disease Control and Prevention growth charts;&#xD;
&#xD;
          2. History of physician diagnosis of asthma or any other clinically important pulmonary&#xD;
             disease, or use of any medications to treat such conditions within the last year;&#xD;
&#xD;
          3. Allergy or known hypersensitivity for AFREZZA or to drugs with similar chemical&#xD;
             structure;&#xD;
&#xD;
          4. Unstable diabetes control, defined as 2 or more episodes of severe hypoglycemia (i.e.,&#xD;
             an episode associated with a seizure, coma, or loss of consciousness) or any&#xD;
             hospitalization or emergency room visit for poor diabetes control, ketoacidosis,&#xD;
             hypoglycemia, or hyperglycemia within the preceding 3 months from screening;&#xD;
&#xD;
          5. Serum creatinine ≥ the upper limit of normal for age;&#xD;
&#xD;
          6. Respiratory tract infection within 30 days before screening or between screening and&#xD;
             initiation of treatment period; subject may return 4 weeks after resolution of the&#xD;
             infection for rescreening;&#xD;
&#xD;
          7. Evidence of any complication of diabetes (proliferative retinopathy, autonomic&#xD;
             neuropathy, nephropathy, etc), or likelihood of requiring laser photocoagulation,&#xD;
             vitrectomy, or other specific treatment for diabetic retinopathy in the coming year;&#xD;
&#xD;
          8. Smoking of tobacco or other substances or positive urine cotinine testing (&gt;100&#xD;
             ng/mL);&#xD;
&#xD;
          9. Positive urine drug screen;&#xD;
&#xD;
         10. Positive urine pregnancy test for female subjects of childbearing potential;&#xD;
&#xD;
         11. Inability to perform study procedures including pulmonary function testing;&#xD;
&#xD;
         12. Exposure to any investigational product(s) in the past 3 months or 5 half-lives,&#xD;
             whichever is more;&#xD;
&#xD;
         13. History of eating disorder;&#xD;
&#xD;
         14. Any disease or exposure to any medication which, in the judgment of the principal&#xD;
             Investigator, may impact glucose metabolism;&#xD;
&#xD;
         15. Any concurrent medical or major psychiatric condition that makes the subject&#xD;
             unsuitable for the clinical study or impairs the subject's ability to participate in&#xD;
             the study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Mannkind Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Diabetes Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Meter Pediatric Endocrinology, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University, Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry J. Reiner, MD, LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <results_first_submitted>February 5, 2021</results_first_submitted>
  <results_first_submitted_qc>March 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02527265/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02527265/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 48 subjects were screened for the study, of which 30 subjects were enrolled in the study (15 subjects each in Cohort 1 and Cohort 2)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afrezza Cohort 1 (Ages 13-17)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive daily injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
        <group group_id="P2">
          <title>Afrezza Cohort 2 (Ages 8-12)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive daily injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Afrezza Cohort 1 (Ages 13-17)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive daily injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
        <group group_id="B2">
          <title>Afrezza Cohort 2 (Ages 8-12)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive daily injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="1.73"/>
                    <measurement group_id="B2" value="10.4" spread="1.55"/>
                    <measurement group_id="B3" value="12.7" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Maximum Observed Concentration (Cmax)</title>
        <description>Insulin Cmax after a dose of Afrezza</description>
        <time_frame>250 minutes post-dose</time_frame>
        <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Afrezza Cohort 1 (Ages 13-17)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
          <group group_id="O2">
            <title>Afrezza Cohort 2 (Ages 8-12)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Maximum Observed Concentration (Cmax)</title>
          <description>Insulin Cmax after a dose of Afrezza</description>
          <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
          <units>μU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="5.77"/>
                    <measurement group_id="O2" value="102" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="42.1"/>
                    <measurement group_id="O2" value="133" spread="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201" spread="118"/>
                    <measurement group_id="O2" value="251" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Time to Reach Cmax (Tmax)</title>
        <description>Insulin Tmax after a dose of Afrezza</description>
        <time_frame>250 minutes post-dose</time_frame>
        <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Afrezza Cohort 1 (Ages 13-17)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
          <group group_id="O2">
            <title>Afrezza Cohort 2 (Ages 8-12)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Time to Reach Cmax (Tmax)</title>
          <description>Insulin Tmax after a dose of Afrezza</description>
          <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="3.54"/>
                    <measurement group_id="O2" value="9.5" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="5.47"/>
                    <measurement group_id="O2" value="14.1" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="3.27"/>
                    <measurement group_id="O2" value="10.0" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Area Under Concentration Time Curve (AUC)</title>
        <description>Insulin AUC after a dose of Afrezza</description>
        <time_frame>250 minutes post-dose</time_frame>
        <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Afrezza Cohort 1 (Ages 13-17)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
          <group group_id="O2">
            <title>Afrezza Cohort 2 (Ages 8-12)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Area Under Concentration Time Curve (AUC)</title>
          <description>Insulin AUC after a dose of Afrezza</description>
          <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
          <units>min*μU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1468" spread="1272"/>
                    <measurement group_id="O2" value="2931" spread="1011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4488" spread="2644"/>
                    <measurement group_id="O2" value="4975" spread="2921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6400" spread="3009"/>
                    <measurement group_id="O2" value="5971" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5778" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)</title>
        <description>FDKP (inert carrier excipient) calculated half life t1/2</description>
        <time_frame>Using PK data collected over 250 minutes post-dose of Afrezza</time_frame>
        <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Afrezza Cohort 1 (Ages 13-17)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
          <group group_id="O2">
            <title>Afrezza Cohort 2 (Ages 8-12)</title>
            <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Fumaryl Diketopiperazine (FDKP) Elimination Half-life (t1/2)</title>
          <description>FDKP (inert carrier excipient) calculated half life t1/2</description>
          <population>All subjects without any major deviations related to study drug administration, and for whom any PK parameters are available, will be included in the PK population.&#xD;
Subjects who sneeze or cough right after AFREZZA inhalation for PK profiling will be considered as important deviations related to IMP and will be excluded for PK analysis.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103" spread="23.0"/>
                    <measurement group_id="O2" value="86.8" spread="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="31.3"/>
                    <measurement group_id="O2" value="86.5" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="25.9"/>
                    <measurement group_id="O2" value="95.5" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 unit cartridge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="NA">n=1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afrezza Cohort 1 (Ages 13-17)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
        <group group_id="E2">
          <title>Afrezza Cohort 2 (Ages 8-12)</title>
          <description>Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.&#xD;
During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day.&#xD;
Afrezza: Pharmaceutical form: powder&#xD;
Route of administration: inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA, Version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urine cotinine test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="45" subjects_affected="10" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development</name_or_title>
      <organization>MannKind Corporation</organization>
      <phone>844.323.7399</phone>
      <email>mapp@mannkindcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

